Core Viewpoint - Huadong Medicine's Biomee®1 and Biomee®2 creams are not yet launched overseas and will be registered as imported cosmetics in China, bypassing the drug approval process and clinical trials [1] Group 1 - The products Biomee®1 and Biomee®2 are currently not available in international markets [1] - The registration process for these products in China will follow the imported cosmetics pathway rather than the drug registration approval route [1] - This approach allows the company to avoid the need for conducting clinical trials domestically [1]

Core Viewpoint - Huadong Medicine (000963) has confirmed that its products Biomee1 and Biomee2 creams are not yet launched overseas and will be registered as imported cosmetics in China, bypassing the drug registration approval process [1] Group 1 - The products Biomee1 and Biomee2 are currently not available in international markets [1] - In China, these products will be registered as imported cosmetics rather than through the drug registration pathway [1] - The registration process for these products does not require clinical trials in China [1]

Group 1 - The core viewpoint of the article is that Huadong Medicine has clarified the registration status of its products Biomee®1 and Biomee®2, indicating they are not yet launched overseas and will be registered as imported cosmetics in China rather than through drug approval pathways [2] Group 2 - Biomee®1 and Biomee®2 will not require clinical trials in China, simplifying the registration process for these products [2]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration (NMPA) for the active pharmaceutical ingredient (API) Apalutamide, which is used in prostate cancer treatment [1] Group 1: Company Information - Tianyu Co., Ltd. has a subsidiary named Zhejiang Jingsheng Pharmaceutical Co., Ltd. that specializes in pharmaceutical production [1] - The company is focused on developing Apalutamide, a non-steroidal anti-androgen drug [1] Group 2: Product Details - Apalutamide is indicated for the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer [1] - The drug works by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression [1] - Apalutamide is intended to be used in conjunction with androgen deprivation therapy under medical supervision [1]

每经AI快讯，京新药业1月7日晚间发布公告称，截至本报告披露日，公司回购股份期限已届满。公司 累计通过股份回购专用证券账户以集中竞价方式回购公司股份4,727.1295万股，占公司目前总股本的 5.49%，购买股份最高成交价为14.41元/股，购买股份最低成交价为11.86元/股，成交总金额为60,872.22 万元（不含交易费用）。本次回购符合相关法律法规的要求，符合公司既定的回购股份方案。 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 （记者 曾健辉） ...

Group 1 - The core viewpoint of the article is that Haichen Pharmaceutical has achieved the required parameters for its lithium sulfide pilot line products and is preparing to send samples [2] - Sichuan Luocheng is a joint venture between the company's subsidiary Anqing Huichen and Saike Power, focusing on the development of solid-state battery binders [2] - The project is currently in the small-scale development stage [2]

（记者 王瀚黎） 每经AI快讯，东诚药业1月7日晚间发布公告称，2026年1月6日，公司首次通过股份回购专用证券账户 以集中竞价方式回购公司股份约122万股，占公司总股本的比例为0.1481%，最高成交价为14.16元/股， 最低成交价为13.89元/股，支付的资金总额为人民币约1719万元。本次回购股份资金来源为公司自有资 金，回购价格未超过回购方案中拟定的价格上限。 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 ...

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation for its active pharmaceutical ingredient, Apalutamide, which is used in the treatment of prostate cancer [1] Group 1 - Apalutamide is a non-steroidal anti-androgen drug that works by inhibiting the androgen receptor signaling pathway to delay disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1] - Apalutamide is to be used in conjunction with castration therapy under medical guidance [1]

Core Viewpoint - The pharmaceutical and medical device sectors in China are expected to experience a convergence of industrial, policy, and capital cycles by 2026, presenting significant investment opportunities in innovative therapies and medical devices [1] Pharmaceutical Industry - The Chinese innovative drug sector is anticipated to reach a performance inflection point and valuation restructuring, with a focus on next-generation therapies such as ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - Research and development spending by pharmaceutical companies is showing marginal improvement, with opportunities for domestic substitution and breakthroughs in mid-to-high-end products [1] Medical Device Industry - The impact of centralized procurement policies is gradually diminishing, while overseas markets continue to grow rapidly, suggesting a recovery in the performance of related companies [1] - Investment focus should be on rapidly scaling products post-procurement implementation and medical device companies driven by equipment upgrades [1] Blood Products Market - The demand for blood products and the volume of plasma collection are consistently increasing, with resources concentrating among leading companies in the sector [1] Investment Opportunities - The overall pharmaceutical industry is entering a critical phase of innovation realization and global expansion, with investment opportunities concentrated in innovative companies that possess global competitiveness [1] ETF Overview - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily price fluctuation limit of 20%, focusing on companies with high R&D investment and innovation capabilities in the pharmaceutical sector [1]